首页 › 基金 › Vestal Point Capital, LP › DRUG

Vestal Point Capital, LP 对 DRUG 的持仓历史

BRIGHT MINDS BIOSCIENCES INC · 医疗保健

Vestal Point Capital, LP 在 Q3 2026 的 13F 申报中披露持有 DRUG(BRIGHT MINDS BIOSCIENCES INC)545,000 股,市值约 US$27.2M,约占其申报组合的 0.70%,在其申报持仓中市值排名第 24 位。 Vestal Point Capital, LP 最近 3 个申报季度中有 3 个季度披露了 DRUG 持仓,最早可追溯至 Q1 2026。

最新持仓 (Q3 2026)545.00K 股
申报持仓市值$27.15M
组合权重0.70%
首次申报Q1 2026
最近变动持有
更新于2026-11-17

最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR

Vestal Point Capital, LP 对 DRUG 的持仓演变

Vestal Point Capital, LP 于 Q1 2026 首次披露 DRUG 持仓:492,319 股(约 US$35.9M)。 该持仓在 Q2 2026 达到峰值 545,000 股,市值约 US$38.3M。 在 3 次申报中,Vestal Point Capital, LP 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 545,000 股、市值约 US$27.2M。

逐季持仓明细

季度股数金额变化
Q1 2026 492.32K $35.92M 新进
Q2 2026 545.00K $38.26M 增持
Q3 2026 545.00K $27.15M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 DRUG 与 13F 数据

DRUG(BRIGHT MINDS BIOSCIENCES INC)属于医疗保健行业。我们追踪的基金中还有 60 只申报持有 DRUG,申报仓位最大的包括:Cormorant Asset Management, LP (US$39.9M), BRAIDWELL LP (US$24.1M), Vivo Capital, LLC (US$20.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 DRUG 的基金

查看 DRUG 的全部基金持有人 →

常见问题

How long has Vestal Point Capital, LP held DRUG?

Vestal Point Capital, LP has disclosed DRUG holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Vestal Point Capital, LP's current position in DRUG?

As of Q3 2026, Vestal Point Capital, LP holds 545.00K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $27.15M, representing 0.70% of its reported portfolio and ranking #24.

Has Vestal Point Capital, LP been buying or selling DRUG?

In the latest 13F filing (Q3 2026), Vestal Point Capital, LP held unchanged its position in DRUG. The position peaked in Q2 2026 at 545.00K shares.

Which other funds hold DRUG?

Other major institutional holders of DRUG include Cormorant Asset Management, LP, BRAIDWELL LP, Vivo Capital, LLC, among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.